U.S. markets closed
  • S&P Futures

    4,075.50
    -8.75 (-0.21%)
     
  • Dow Futures

    33,995.00
    -51.00 (-0.15%)
     
  • Nasdaq Futures

    12,188.00
    -34.25 (-0.28%)
     
  • Russell 2000 Futures

    1,914.90
    -4.60 (-0.24%)
     
  • Crude Oil

    79.94
    +0.26 (+0.33%)
     
  • Gold

    1,942.30
    -3.30 (-0.17%)
     
  • Silver

    23.74
    +0.12 (+0.50%)
     
  • EUR/USD

    1.0872
    -0.0002 (-0.02%)
     
  • 10-Yr Bond

    3.5180
    +0.0250 (+0.72%)
     
  • Vix

    18.51
    -0.22 (-1.17%)
     
  • GBP/USD

    1.2389
    -0.0006 (-0.05%)
     
  • USD/JPY

    130.1160
    +0.3120 (+0.24%)
     
  • BTC-USD

    23,649.78
    +482.14 (+2.08%)
     
  • CMC Crypto 200

    537.05
    +20.04 (+3.88%)
     
  • FTSE 100

    7,765.15
    +4.04 (+0.05%)
     
  • Nikkei 225

    27,470.11
    +87.55 (+0.32%)
     

Aeglea Nosedives After Clinical Update On Investigational Candidate For Rare Metabolism Disease

  • Aeglea BioTherapeutics Inc (NASDAQ: AGLE) has appointed Jeffrey M. Goldberg as president, chief executive officer, and a board member, effective November 29, 2022.

  • Jim Kastenmayer will step down as interim chief executive officer and retain his position as Aeglea's general counsel.

  • Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing Phase 1/2 trial of pegtarviliase in Classical Homocystinuria in the fourth quarter of 2022.

  • Enrollment in the third cohort of the Phase 1/2 trial is ongoing, with two patients having completed dosing in the cohort.

  • In October, the FDA placed a partial clinical hold for enrolling patients under 18 years of age under the Phase 1/2 trial of pegtarviliase for Classical Homocystinuria Investigational New Drug (IND).

  • Additionally, the company has decided not to participate in the Piper Sandler 34th Annual Healthcare Conference and the 5th Annual Evercore ISI HealthCONx Conference.

  • Aeglea looks forward to delivering a clinical update on the pegtarviliase program when more comprehensive data from the third cohort becomes available.

  • Price Action: AGLE shares are down 58.9% at $0.5010 on the last check Wednesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.